Medicine · 2025
Efficacy and safety of YHC-BE-2040 on immune function: An 8-week, multicenter, randomized, double-blinded, and placebo-controlled study.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Ji-Ryang, Kim Seung Jae, Kim Kyoung Kon, Kim Young Sang, Lee Yun-Ah, Song Sang-Wook
Аннотация
BACKGROUND: Deer velvet (DV) extract, a traditional remedy in Eastern Asian medicine, holds potential as an immune modulator. This study aimed to investigate the effects of enzymatically digested DV extract, YHC-BE-2040 (HENKIV®), on cell-mediated immunity in a randomized controlled trial.
METHODS: Healthy adults (N = 120), aged 40 to 70, were randomly assigned to receive either a high-dose (HD) or low-dose (LD) DV extract, or a placebo daily for 8 weeks. The subjects were instructed to orally administer the provided intervention once a day, taking 2 capsules per dose after a meal.
RESULTS: Primary efficacy was measured by natural killer-cell activity, revealing a significant increase in both HD and LD groups compared to placebo (P < .05). Notably, a dose-response relationship was observed, with the HD group exhibiting the most substantial improvement. Secondary parameters TNF-α, IFN-γ, IL-2, and IL-6 showed significant increases in IFN-γ for HD and LD groups. Safety analysis revealed that YHC-BE-2040 was well-tolerated, with no serious adverse events. Reported adverse events were mild to moderate and not definitively linked to the intervention.
CONCLUSION: This study provides meaningful insights into the potential of YHC-BE-2040 as an immune function modulator. While promising, further research with clinical endpoints, larger sample sizes, and extended study durations is needed to fully understand the mechanisms and long-term effects of this deer antler extract on human immunity. Nevertheless, these findings support the safe and effective use of YHC-BE-2040 as an immune-enhancing dietary supplement in healthy adults.
METHODS: Healthy adults (N = 120), aged 40 to 70, were randomly assigned to receive either a high-dose (HD) or low-dose (LD) DV extract, or a placebo daily for 8 weeks. The subjects were instructed to orally administer the provided intervention once a day, taking 2 capsules per dose after a meal.
RESULTS: Primary efficacy was measured by natural killer-cell activity, revealing a significant increase in both HD and LD groups compared to placebo (P < .05). Notably, a dose-response relationship was observed, with the HD group exhibiting the most substantial improvement. Secondary parameters TNF-α, IFN-γ, IL-2, and IL-6 showed significant increases in IFN-γ for HD and LD groups. Safety analysis revealed that YHC-BE-2040 was well-tolerated, with no serious adverse events. Reported adverse events were mild to moderate and not definitively linked to the intervention.
CONCLUSION: This study provides meaningful insights into the potential of YHC-BE-2040 as an immune function modulator. While promising, further research with clinical endpoints, larger sample sizes, and extended study durations is needed to fully understand the mechanisms and long-term effects of this deer antler extract on human immunity. Nevertheless, these findings support the safe and effective use of YHC-BE-2040 as an immune-enhancing dietary supplement in healthy adults.